Stock Research for AMAG

AMAG

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AMAG Stock Chart & Research Data

The AMAG chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMAG chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AMAG Due diligence Resources & Stock Charts

The AMAG stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AMAG Detailed Price Forecast - CNN Money CNN View AMAG Detailed Summary - Google Finance
Yahoo View AMAG Detailed Summary - Yahoo! Finance Zacks View AMAG Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AMAG Trends & Analysis - Trade-Ideas Barrons View AMAG Major Holders - Barrons
NASDAQ View AMAG Call Transcripts - NASDAQ Seeking View AMAG Breaking News & Analysis - Seeking Alpha
Spotlight View AMAG Annual Report - CompanySpotlight.com OTC Report View AMAG OTC Short Report - OTCShortReport.com
TradeKing View AMAG Fundamentals - TradeKing Charts View AMAG SEC Filings - Bar Chart
WSJ View Historical Prices for AMAG - The WSJ Morningstar View Performance/Total Return for AMAG - Morningstar
MarketWatch View the Analyst Estimates for AMAG - MarketWatch CNBC View the Earnings History for AMAG - CNBC
StockMarketWatch View the AMAG Earnings - StockMarketWatch MacroAxis View AMAG Buy or Sell Recommendations - MacroAxis
Bullish View the AMAG Bullish Patterns - American Bulls Short Pains View AMAG Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AMAG Stock Mentions - StockTwits PennyStocks View AMAG Stock Mentions - PennyStockTweets
Twitter View AMAG Stock Mentions - Twitter Invest Hub View AMAG Investment Forum News - Investor Hub
Yahoo View AMAG Stock Mentions - Yahoo! Message Board Seeking Alpha View AMAG Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AMAG - SECform4.com Insider Cow View Insider Transactions for AMAG - Insider Cow
CNBC View AMAG Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AMAG - OTC Markets
Yahoo View Insider Transactions for AMAG - Yahoo! Finance NASDAQ View Institutional Holdings for AMAG - NASDAQ


Stock Charts

FinViz View AMAG Stock Insight & Charts - FinViz.com StockCharts View AMAG Investment Charts - StockCharts.com
BarChart View AMAG Stock Overview & Charts - BarChart Trading View View AMAG User Generated Charts - Trading View




Latest Financial News for AMAG


Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
Posted on Monday June 24, 2019

on Monday jumped and then pulled back after the biopharma was cleared by the U.S. Food and Drug Administration to market a drug to treat weakened sexual desire in women. Palatin shares were trading off 6.72% at $1.25. The FDA cleared Vyleesi, a treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder, Palatin said.


Palatin's stock rockets after FDA OK to market sexual desire disorder treatment
Posted on Monday June 24, 2019

Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc.'s treatment for hypoactive sexual desire disorder (HSDD) triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for AMAG's new drug application (NDA) for Vyleesi, which was developed by Palatin. AMAG's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with AMAG, Palatin is also entitled to receive royalties on sales, ranging from high single-digit to low double-digit percentage ranges, and other milestone payments based on escalating annual sales thresholds. Palatin's stock has rallied 23% over the past 12 months and AMAG shares have tumbled 59%, while the S&P 500 has gained 7.1%.


The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Posted on Saturday June 22, 2019

Biotech stocks came made upward moves last week after a rangebound period.  Among big pharma companies, Merck & Co., Inc. (NYSE: MRK ) was a standout gainer, notching up 52-week highs in successive sessions, ...


AMAG stock rallies on FDA approval for drug to increase women's sex drive
Posted on Friday June 21, 2019

The U.S. Food and Drug Administration late Friday approved a drug to treat low libido in women, and shares of the company slated to market the medication, AMAG Pharmaceuticals Inc. , shot more than 16% in the extended session. The drug, Vyleesi, is aimed at premenopausal women in whom low sex drive causes distress. It comes in an auto-injecting pen that can be used ahead of sexual activity. Vyleesi is expected to be commercially available in September. AMAG licensed Vyleesi from Palatin Technologies Inc. and under the terms of their agreement the FDA approval triggers a $60 million payment to Palatin, plus tiered royalties tied to sales milestones. Shares of Palatin rallied 30% in the extended session. Both stocks ended the regular trading day more than 4% higher.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.